Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose MK-8408 study in adults with hepatitis C infection
NL-OMON41065Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ruzasvir in hepatitis C virus infection, sponsored by Merck & Co. Primary endpoints: Viral load reduction, Safety and 1 more. Started Aug 2014; status: active, not recruiting.
02
Drugs
ruzasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON41065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41065.